AdvanCell Secures $112M in Oversubscribed Series C Funding
Deal News | Feb 03, 2025 | SV Health Investors, LLC
AdvanCell, an innovative clinical-stage radiopharmaceutical company based in Sydney, Australia, has successfully raised $112 million in an oversubscribed Series C funding round. This financing, co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis, also includes contributions from existing and new investors such as Morningside, Tenmile, and Brandon Capital. The funds will reinforce AdvanCell's initiatives to expand its manufacturing capabilities, advance the clinical development of its targeted radionuclide therapies for cancer treatment, and accelerate patient enrollment in ongoing trials. Key additions to the board of directors from the leading investors underscore significant industry backing for AdvanCell's vision. This financial milestone fortifies AdvanCell's path towards becoming a leader in the development of radionuclide-based cancer treatments.
Sectors
- Biotechnology
- Life Sciences
- Healthcare Investment
Geography
- Australia – AdvanCell is based in Sydney, Australia, and this location is central to its identity and operations.
- United States – SV Health Investors, along with other leading investors, operates transatlantically, with a notable presence in the United States.
- United Kingdom – The presence of Abingworth, a key investor in the funding round, suggests relevance to the UK, particularly within the life sciences investment sphere.
Industry
- Biotechnology – AdvanCell is involved in the development of innovative cancer treatments, leveraging biotechnology to create targeted radiopharmaceutical therapies.
- Life Sciences – The focus on advancing radionuclide therapies indicates involvement in the life sciences sector, which deals with the study and application of biology to health.
- Healthcare Investment – The article discusses a significant investment event involving multiple healthcare-focused investment firms, highlighting a connection to the healthcare investment industry.
Financials
- US$112M – Total amount raised in the oversubscribed Series C funding round for AdvanCell.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| AdvanCell | Target | Company | A clinical-stage radiopharmaceutical company developing innovative cancer therapeutics based in Sydney, Australia. |
| SV Health Investors | Co-lead investor | Company | A leading healthcare fund manager investing in healthcare innovations, with a transatlantic presence. |
| Sanofi Ventures | Co-lead investor | Company | The corporate venture capital arm of Sanofi, focused on early-stage healthcare investments. |
| Abingworth | Co-lead investor | Company | A transatlantic life sciences investment firm providing capital and expertise for building world-class companies. |
| SymBiosis | Co-lead investor | Company | An investment firm focused on advancing biotherapeutic innovations for serious diseases. |
| Morningside | Existing investor | Company | A supporter of AdvanCell's growth through continued investment in its funding rounds. |
| Tenmile | New investor | Company | One of the new investors participating in the Series C funding round. |
| Brandon Capital | New investor | Company | A new investor contributing to the Series C funding round for AdvanCell. |